Basilea Pharmaceutica Balance Sheet Health
Financial Health criteria checks 0/6
Basilea Pharmaceutica has a total shareholder equity of CHF-10.0M and total debt of CHF110.9M, which brings its debt-to-equity ratio to -1108.7%. Its total assets and total liabilities are CHF173.3M and CHF183.3M respectively. Basilea Pharmaceutica's EBIT is CHF21.9M making its interest coverage ratio 2.3. It has cash and short-term investments of CHF59.9M.
Key information
-1,108.7%
Debt to equity ratio
CHF110.91m
Debt
| Interest coverage ratio | 2.3x |
| Cash | CHF59.93m |
| Equity | -CHF10.00m |
| Total liabilities | CHF183.29m |
| Total assets | CHF173.29m |
Recent financial health updates
No updates
Recent updates
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now
Apr 18
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
Sep 20Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Feb 17Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Jul 01Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long
Mar 24If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%
Feb 18Financial Position Analysis
Short Term Liabilities: BSLN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BSLN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BSLN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BSLN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: BSLN's debt is not well covered by operating cash flow (12.8%).
Interest Coverage: BSLN's interest payments on its debt are not well covered by EBIT (2.3x coverage).